Quidel (NASDAQ:QDEL)‘s stock had its “buy” rating restated by research analysts at Piper Jaffray Companies in a research note issued on Wednesday. They presently have a $60.00 price target on the stock. Piper Jaffray Companies’ price target would indicate a potential upside of 23.56% from the company’s previous close.
A number of other analysts have also weighed in on QDEL. Barclays increased their price objective on shares of Quidel from $50.00 to $60.00 and gave the stock an “overweight” rating in a research report on Monday, January 22nd. Canaccord Genuity reissued a “buy” rating and issued a $48.00 price objective on shares of Quidel in a research report on Wednesday, October 25th. BidaskClub raised shares of Quidel from a “hold” rating to a “buy” rating in a research report on Thursday, December 21st. CL King raised shares of Quidel from a “neutral” rating to a “buy” rating and set a $52.00 price objective on the stock in a research report on Thursday, January 4th. Finally, Zacks Investment Research lowered shares of Quidel from a “hold” rating to a “strong sell” rating in a research report on Thursday, December 28th. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. Quidel presently has a consensus rating of “Buy” and a consensus price target of $53.50.
Quidel (NASDAQ:QDEL) traded down $0.05 during trading on Wednesday, reaching $48.56. 276,655 shares of the company were exchanged, compared to its average volume of 302,622. The company has a debt-to-equity ratio of 0.70, a current ratio of 6.28 and a quick ratio of 5.68. Quidel has a 12 month low of $18.25 and a 12 month high of $49.47. The stock has a market cap of $1,652.59, a price-to-earnings ratio of -323.71, a P/E/G ratio of 1.57 and a beta of 1.15.
In related news, Director Jack W. Schuler sold 4,000 shares of Quidel stock in a transaction that occurred on Friday, January 5th. The shares were sold at an average price of $47.02, for a total transaction of $188,080.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Douglas C. Bryant sold 12,000 shares of Quidel stock in a transaction that occurred on Tuesday, November 28th. The shares were sold at an average price of $36.72, for a total transaction of $440,640.00. Following the transaction, the chief executive officer now directly owns 296,493 shares in the company, valued at $10,887,222.96. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 385,790 shares of company stock worth $15,834,675. Corporate insiders own 22.00% of the company’s stock.
A number of hedge funds have recently modified their holdings of QDEL. Legal & General Group Plc increased its holdings in Quidel by 4.0% during the second quarter. Legal & General Group Plc now owns 7,209 shares of the company’s stock valued at $197,000 after buying an additional 278 shares during the period. Great West Life Assurance Co. Can increased its holdings in Quidel by 162.7% during the third quarter. Great West Life Assurance Co. Can now owns 4,642 shares of the company’s stock valued at $204,000 after buying an additional 2,875 shares during the period. Jane Street Group LLC purchased a new position in Quidel during the third quarter valued at approximately $205,000. Russell Investments Group Ltd. purchased a new position in Quidel during the second quarter valued at approximately $209,000. Finally, C M Bidwell & Associates Ltd. purchased a new position in Quidel during the second quarter valued at approximately $364,000. 92.69% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Quidel (QDEL) Given “Buy” Rating at Piper Jaffray Companies” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://www.americanbankingnews.com/2018/01/28/quidel-qdel-given-buy-rating-at-piper-jaffray-companies.html.
Quidel Company Profile
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers.
Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.